Why is Levemir Discontinued?
Novo Nordisk is discontinuing Levemir (insulin detemir) in the U.S. market by the end of 2022 [1]. This decision is part of a broader strategy to streamline the company's insulin portfolio and focus on newer, more advanced diabetes medications [1].
What are the alternatives to Levemir?
Patients using Levemir will need to transition to alternative insulin treatments. Novo Nordisk is recommending Tresiba (insulin degludec) as a direct replacement for Levemir [1]. Tresiba is another long-acting basal insulin that offers a different duration of action and dosing flexibility [2]. Other long-acting insulin analogs, such as Lantus (insulin glargine) and Toujeo (insulin glargine), are also available alternatives [3].
When does patent exclusivity expire for Levemir?
The patent for Levemir has expired, allowing for the potential development of generic or biosimilar versions. However, the discontinuation by Novo Nordisk is a commercial decision, not solely driven by patent expiration [1]. Information on specific patent expiry dates and potential generic entries can be found on DrugPatentWatch.com [4].
What are the implications for patients?
The discontinuation of Levemir will require patients to work with their healthcare providers to switch to a new insulin regimen [1]. This transition may involve adjustments to dosage and monitoring to ensure continued glycemic control. Patients should discuss any concerns about switching insulins with their doctor to ensure a smooth and effective transition [1].
Why are companies phasing out older insulins?
Pharmaceutical companies often discontinue older medications, including insulins, as part of their product lifecycle management. This allows them to focus resources on developing and marketing newer, often more profitable, medications with improved efficacy, safety profiles, or dosing convenience [1]. The availability of advanced insulins like Tresiba also plays a role in this strategic shift.
*
**Sources:
[1] https://www.novocare.com/diabetes/our-products/levemir-discontinuation.html
[2] https://www.novocare.com/diabetes/our-products/tresiba.html
[3] https://www.mayoclinic.org/diseases-conditions/diabetes/in-depth/insulin/art-20044945
[4] https://www.drugpatentwatch.com/